RGEN
REPLIGEN CORP
Key Financials
Revenue
$141.2M
↑ 239.4%
Net Income
$48.9M
↑ 291.6%
Gross Profit
$60.5M
↑ 11.1%
Operating Income
$55.2M
↑ 257.1%
EPS (Diluted)
$0.86
↑ 287.0%
Total Assets
$2.9B
↑ 4.2%
Total Liabilities
$843.6M
↓ 1.6%
Long-term Debt
$542.2M
↑ 3.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| ARS | 4/2/2026 | View on SEC |
| DEFA14A | 4/2/2026 | View on SEC |
| DEF 14A | 4/2/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 4 | 3/23/2026 | View on SEC |
| 4 | 3/5/2026 | View on SEC |
| 4 | 3/5/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RGEN |
| Company Name | REPLIGEN CORP |
| CIK | 730272 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 7814499560 |